ATYR Atyr Pharma Inc
Price (delayed)
$1.88
Market cap
$142.5M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.91
Enterprise value
$146.65M
atyr pharma (nasdaq: life) is engaged in the discovery and clinical development of innovative medicines for patients suffering from severe rare diseases using its knowledge of physiocrine biology, a newly
Highlights
ATYR's EPS is up by 26% year-on-year
The debt has contracted by 10% YoY
Atyr Pharma's quick ratio has increased by 24% from the previous quarter but it has decreased by 23% YoY
The revenue has shrunk by 94% YoY
The company's gross profit has shrunk by 94% YoY
Key stats
What are the main financial stats of ATYR
Market
Valuations
Earnings
Shares outstanding
75.8M
Market cap
$142.5M
Enterprise value
$146.65M
Price to earnings (P/E)
N/A
Price to book (P/B)
1.59
Price to sales (P/S)
231.11
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
249.4
Revenue
$588,000
EBIT
-$57.9M
EBITDA
-$55.34M
Free cash flow
-$64.05M
Per share
Balance sheet
Liquidity
EPS
-$0.91
Free cash flow per share
-$0.89
Book value per share
$1.18
Revenue per share
$0.01
TBVPS
$1.47
Total assets
$105.94M
Total liabilities
$24.52M
Debt
$13.85M
Equity
$81.61M
Working capital
$78.46M
Debt to equity
0.17
Current ratio
7.63
Quick ratio
7.01
Net debt/EBITDA
-0.07
Margins
Efficiency
Dividend
EBITDA margin
-9,412.2%
Gross margin
100%
Net margin
-9,846.4%
Operating margin
-10,633.5%
Return on assets
-49.8%
Return on equity
-65.2%
Return on invested capital
-56.9%
Return on capital employed
-61.5%
Return on sales
-9,846.4%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
ATYR stock price
How has the Atyr Pharma stock price performed over time
Intraday
7.43%
1 week
0.53%
1 month
0.53%
1 year
13.94%
YTD
33.33%
QTD
20.51%
Financial performance
How have Atyr Pharma's revenue and profit performed over time
Revenue
$588,000
Gross profit
$588,000
Operating income
-$62.53M
Net income
-$57.9M
Gross margin
100%
Net margin
-9,846.4%
The revenue has shrunk by 94% YoY
The company's gross profit has shrunk by 94% YoY
Atyr Pharma's operating income has decreased by 31% YoY and by 6% from the previous quarter
The net income has contracted by 29% YoY and by 7% from the previous quarter
Growth
What is Atyr Pharma's growth rate over time
Valuation
What is Atyr Pharma stock price valuation
P/E
N/A
P/B
1.59
P/S
231.11
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
249.4
ATYR's EPS is up by 26% year-on-year
ATYR's P/B is 33% above its 5-year quarterly average of 1.2 and 33% above its last 4 quarters average of 1.2
The company's equity fell by 23% YoY and by 3.4% QoQ
The revenue has shrunk by 94% YoY
ATYR's P/S is 46% above its last 4 quarters average of 158.4
Efficiency
How efficient is Atyr Pharma business performance
The return on equity has declined by 32% year-on-year and by 15% since the previous quarter
The ROA has contracted by 27% YoY and by 13% from the previous quarter
The company's return on invested capital fell by 22% YoY and by 13% QoQ
ATYR's ROS is down by 7% since the previous quarter
Dividends
What is ATYR's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for ATYR.
Financial health
How did Atyr Pharma financials performed over time
The current ratio has grown by 26% from the previous quarter but it has contracted by 18% YoY
Atyr Pharma's quick ratio has increased by 24% from the previous quarter but it has decreased by 23% YoY
The debt is 83% less than the equity
The company's equity fell by 23% YoY and by 3.4% QoQ
ATYR's debt to equity is up by 21% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.